FIXX News and Press, Homology Medicines Inc. From 11/15/21

Homology Medicines (NASDAQ:FIXX): Q3 GAAP EPS of -$0.54 beats by $0.08. Revenue of $1.67M (+193.0% Y/Y) beats by $0.87M. Press Release For further details see: Homology Medicines EPS beats by $0.08, beats on revenue

- Achieved Goal of Three Clinical Programs Across Gene Therapy and Gene Editing Technology Platform This Year - - Start of First Gene Editing Trial Advances Mission to Develop Solutions for Both Adults and Pediatric Patients with PKU - - Initiated juMPStart Trial of One-...

- Data Support PKU and Hunter Syndrome Clinical Trials and PNH Program - BEDFORD, Mass., Oct. 21, 2021 (GLOBE NEWSWIRE) --  Homology Medicines, Inc. (Nasdaq: FIXX), a genetic medicines company, announced today four presentations of preclinical data spanning its clinical-stage g...

- Oral Presentation on In Vivo Gene Therapy Product Candidate and Data on Gene Editing Candidate Paved Way for Initiation of juMPStart and pheEDIT Trials - BEDFORD, Mass., Oct. 20, 2021 (GLOBE NEWSWIRE) -- Homology Medicines, Inc. (Nasdaq: FIXX), a genetic medicines company, announc...

- juMPStart Trial to Evaluate First Systemic Gene Therapy Candidate for Patients with Hunter Syndrome - BEDFORD, Mass., Oct. 18, 2021 (GLOBE NEWSWIRE) -- Homology Medicines, Inc. (Nasdaq: FIXX), a genetic medicines company, announced today that it has initiated the Phase 1 trial f...

Gainers: Homology Medicines (NASDAQ:FIXX) +6%. Chimerix (NASDAQ:CMRX) +5%. Vimeo (NASDAQ:VMEO) +5%. View (NASDAQ:VIEW) +4%. SMART Global Holdings (NASDAQ:SGH) +4%. Losers: Neuronetics (NASDAQ:STIM) -22%. Quotient Limited (NASDAQ:QTNT) -9%. CRISPR Therapeutics (NASDAQ:CRSP) -8%. Sare...

- IND Clearance of pheEDIT Study to Evaluate a One-Time Dose of Investigational HMI-103 Incorporating a Novel Nuclease-Free Gene Editing Approach - - Company Provides Update on Enrollment in Ongoing pheNIX Trial of HMI-102 Gene Therapy for Adults with PKU - BEDFORD, Mass., O...

- On Track to Report Initial Results from Phase 2 pheNIX Gene Therapy Trial for Adults with PKU in 2021- - Plans to Initiate First-Ever Gene Editing Trial for PKU with HMI-103 This Year - - Expects to Commence Clinical Trial with HMI-203 In Vivo Gene Therapy ...

- ASGCT President and Entrepreneur Takes Leadership Role on SAB as Company Expects to Have Three Clinical Programs in 2021 - BEDFORD, Mass., Aug. 05, 2021 (GLOBE NEWSWIRE) -- Homology Medicines, Inc. (Nasdaq: FIXX), a clinical-stage genetic medicines company, announced today the a...

BEDFORD, Mass., Aug. 04, 2021 (GLOBE NEWSWIRE) -- Homology Medicines, Inc. (Nasdaq: FIXX), a clinical-stage genetic medicines company, announced today participation in fireside chats at the following virtual conferences: BTIG Virtual Biotechnology Conference: August 9 at 1:30 p.m. E...